The first edition of Target Research for 2016 is now available to read online.
It gives a roundup of the latest news on research into muscle-wasting conditions as well as an update on latest information on potential drug license applications and clinical trials.
In this issue, you can read about the use of harmless viruses (AAVs) for the treatment of muscle-wasting conditions such as Duchenne muscular dystrophy and spinal muscular atrophy. There’s also a report from the ninth UK Neuromuscular Translational Research Conference, which provides a platform for scientists and clinicians in the neuromuscular field to discuss their latest findings.
Read previous editions of Target MD.